ClinicalTrials.gg
TerminatedNCT04816604Updated Nov 5, 2026

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of GB002 (seralutinib) and Generic Dry Powder Inhaler in Pulmonary Arterial Hypertension, sponsored by Gossamer Bio USA, Inc.. Terminated at 28 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Gossamer Bio USA, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.
Updated Oct 7, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
83rd of 253
74 · median 40
Started
2021
with 23 others
Phase 2
82 of 312
11 open now
Registered
244th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 83rd largest by enrollment of the 253 interventional ones that give a count, is one of 24 that started in 2021, is one of 82 in phase 2, and was the 244th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • seralutinib
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Type of Subject and Disease Characteristics

  1. Subjects must have completed a prior GB002 PAH study and, in the opinion of the Investigator and Sponsor, have been compliant with study procedures and have completed treatment with IP through parent study end-of-treatment (EOT) visit.
  2. Treatment with standard of care PAH disease-specific background therapies (stable dose).

  3. Review and signature of an IRB-approved informed consent form.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Persistent and systemic hypertension or hypotension.
  2. Interval history of newly developed left-sided heart disease.
  3. Potentially life-threatening cardiac arrhythmia with an ongoing risk.
  4. Uncontrolled bacterial, viral, or fungal infections which require systemic therapy.
  5. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or GB002 administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  6. History of portopulmonary hypertension or portal hypertension due to cirrhosis classified as Class A or higher.
  7. Subjects with a history of severe milk protein allergy. In addition, subjects with known intolerance or to lactose who, in the opinion of the investigator, may experience severe symptoms following the ingestion of lactose.
  8. Current use of inhaled tobacco and/or inhaled marijuana. Ingestible or topical marijuana is allowed, per local restrictions and regulations.
  9. Current alcohol use disorder as defined by , and/or history of current utilization of drugs of abuse (amphetamines, methamphetamines, cocaine, phencyclidine [PCP]).
  10. Have any other condition or reason that, in the opinion of the Investigator and/or the Sponsor's Medical Monitor (or designee), would prohibit the subject from participating in the study.

    Diagnostic Assessments

  11. Chronic renal insufficiency
  12. (Hgb) concentration \<8.5 g/dL.
  13. (ANC) \< 1x 10\^9/L.
  14. count \<50 x 10\^9/L.

    Prior Therapy

  15. Use of inhaled prostanoids.
  16. Chronic use of oral anticoagulants (ie, vitamin K antagonist such as warfarin or novel oral anticoagulant [NOAC]/direct oral anticoagulant [DOAC]).
  17. Chronic use of any prohibited medication.

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    GB002 (seralutinib)

    GB002 (seralutinib) inhaled orally twice per day (BID)

    Drug: GB002 (seralutinib) · Device: Generic Dry Powder Inhaler

Interventions

  • Capsule containing GB002 (seralutinib)

  • DeviceGeneric Dry Powder Inhaler

    Generic dry powder inhaler for GB002 (seralutinib) delivery

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    Time frame: From first dose of study drug up to 80 months or availability of commercial product

Secondary outcomes

  1. Change from Baseline Over Time on the Six-Minute Walk Test (6MWT)

    Change in the distance achieved on the 6MWT (Δ6MWT)

    Time frame: Baseline, up to 80 months or availability of commercial product

07

Study locations

28 sites
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Medical Corporation
    Santa Barbara, California 93105, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Norton Pulmonary Specialists
    Louisville, Kentucky 40202, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • New York Presbyterian Hospital - Weill Cornell Medicine
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • INTEGRIS Baptist Medical Center, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah Health
    Salt Lake City, Utah 84132, United States
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Všeobecná fakultní nemocnice v Praze
    Prague, 128 08, Czechia
  • AP-HP Hôpital de Bicêtre
    Le Kremlin-Bicêtre, 94270, France
  • DRK Kliniken Berlin
    Berlin, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik IV und V
    Giessen, Germany
  • Klinik für Pneumologie, Klinisches Studienzentrum Medizinische Hochschule
    Hanover, 30625, Germany
  • Thoraxklinik-Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • Klinik und Poliklinik f. Innere Medizin II Universitätsklinikum Regensburg
    Regensburg, 93053, Germany
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Royal Papworth Hospital NHS Foundation Trust
    Cambridge, CB2 OAY, United Kingdom
  • Imperial College Healthcare NHS Trust - Hammersmith Medicines Research Limited
    London, United Kingdom
08

References and documents

Publications

  • Sitbon O, Sahay S, Escribano Subias P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, McLaughlin VV, Vachiery JL, Zamanian RT, Ter Veer A, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Howard LS; TORREY Study Investigators. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Adv Ther. 2025 Oct;42(10):5104-5123. doi: 10.1007/s12325-025-03297-2. Epub 2025 Aug 11. PubMed 40788460 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Sep 2026, 65 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Dec 2027 → Sep 2026 and completion Dec 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 25, 2021
StartActual
Apr 5, 2021
Primary completionActual
Sep 9, 2026was Dec 2027
CompletionActual
Sep 9, 2026was Dec 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.
changed Oct 7, 2026
Primary completion
Dec 2027→Sep 9, 2026 (actual)
Oct 7, 2026
Study completion
Dec 2027→Sep 9, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Terminated
    Why stopped Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.
    Primary completion Dec 2027→Sep 9, 2026 (now actual)
    Study completion Dec 2027→Sep 9, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04816604
Lead sponsor
Gossamer Bio USA, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Apr 5, 2021
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update
Nov 5, 2026

Study contacts

Robert Roscigno
study director · Gossamer Bio USA, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seralutinib

Start the discussion